Business Description
Protagonist Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74366E1029
Total Employee Number:
131Description
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 56.03 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 112.28 | |||||
Beneish M-Score | 0.9 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.1 | |||||
3-Year EBITDA Growth Rate | 2.5 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year Book Growth Rate | 31 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.16 | |||||
9-Day RSI | 77.48 | |||||
14-Day RSI | 71.55 | |||||
3-1 Month Momentum % | -5.71 | |||||
6-1 Month Momentum % | 13.79 | |||||
12-1 Month Momentum % | 79.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 17.76 | |||||
Quick Ratio | 17.76 | |||||
Cash Ratio | 15.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.2 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -192.36 | |||||
Net Margin % | -154.88 | |||||
EBITDA Margin % | -190.4 | |||||
FCF Margin % | -159.18 | |||||
OCF Margin % | -157.48 | |||||
ROE % | -17.53 | |||||
ROA % | -16.26 | |||||
ROIC % | -104.55 | |||||
3-Year ROIIC % | -26.02 | |||||
ROC (Joel Greenblatt) % | -1180.17 | |||||
ROCE % | -21.38 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 27.61 | |||||
PS Ratio | 113.82 | |||||
PB Ratio | 12.01 | |||||
Price-to-Tangible-Book | 12.01 | |||||
EV-to-EBIT | -51.56 | |||||
EV-to-EBITDA | -52.09 | |||||
EV-to-Revenue | 99.18 | |||||
EV-to-Forward-Revenue | 12.42 | |||||
EV-to-FCF | -62.3 | |||||
Price-to-GF-Value | 2.09 | |||||
Price-to-Projected-FCF | 32.95 | |||||
| Price-to-Net-Current-Asset-Value | 13.77 | |||||
| Price-to-Net-Cash | 15.56 | |||||
Earnings Yield (Greenblatt) % | -1.94 | |||||
FCF Yield % | -1.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PTGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protagonist Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 74.063 | ||
| EPS (TTM) ($) | -1.81 | ||
| Beta | 0.6749 | ||
| 3-Year Sharpe Ratio | 1.12 | ||
| 3-Year Sortino Ratio | 2.06 | ||
| Volatility % | 35.54 | ||
| 14-Day RSI | 71.55 | ||
| 14-Day ATR ($) | 4.96951 | ||
| 20-Day SMA ($) | 110.5155 | ||
| 12-1 Month Momentum % | 79.82 | ||
| 52-Week Range ($) | 49.38 - 126.59 | ||
| Shares Outstanding (Mil) | 64.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protagonist Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protagonist Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 36 days | ||
| General meeting for 2026 | 2026-06-17 10:00 | 110.64 (-2.66%) | ||
| Guidance call for 2026 | 2026-06-10 09:20 | 105.87 (+6.12%) | ||
| Guidance call for 2026 | 2026-06-03 09:55 | 93.23 (-0.65%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 99.52 (+1.55%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-12 11:30 | 96.48 (-0.37%) | ||
| Citizens Life Sciences Conference | 2026-03-11 13:05 | 97.05 (+1.07%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 16:20 | 92.09 (+2.37%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 11:50 | 94.24 (+2.35%) |
Show
Entries
Protagonist Therapeutics Inc Frequently Asked Questions
What is Protagonist Therapeutics Inc(PTGX)'s stock price today?
The current price of PTGX is $122.58. The 52 week high of PTGX is $126.59 and 52 week low is $49.38.
When is next earnings date of Protagonist Therapeutics Inc(PTGX)?
The next earnings date of Protagonist Therapeutics Inc(PTGX) is 2026-08-06 Est..
Does Protagonist Therapeutics Inc(PTGX) pay dividends? If so, how much?
Protagonist Therapeutics Inc(PTGX) does not pay dividend.
Guru Commentaries on NAS:PTGX
No articles.
Press Release
Articles on Protagonist Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 12, 2026
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Benzinga • 9:47am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers